Now picture a modern organic chemistry lab. The chemist appears to be carrying out a standard reaction: A + B yields C. But now A is actually a mixture of five components while B may be a composite of 10. Instead of a single product C, the chemist deliberately produces a mixture of 50 different compounds! In the not-too-distant past, the second scenario might have been the trademark of a somewhat sloppy chemist or the consequences of a set of very impure reagents. But today, such mixtures of products--combinatorial chemistry--are being heralded as the future of pharmaceutical research. Others see in this the genesis of a new revolution in the search for superconductors or other space-age materials. Whether heresy or panacea, combinatorial chemistry is here to stay. Once the similarities between natural product extraction and deliberate mixture production were recognized, the dogma that chemical entities should be synthesized, purified and analyzed one at a time began to erode. The result is a somewhat tumultuous, totally controversial, but infinitely exciting and challenging new future for the chemical sciences. Some laboratories are deliberately preparing (and successfully decoding) mixtures as large as 200 billion separate compounds in each product vial. Meanwhile, analytical chemists are busy improving both the sensitivity and the resolution capabilities of their diverse groups of hyphenated instruments (GC-MS, LC-MS, MS-MS, CZE-MS, etc.) in order to keep up with the demands of mixture analysis.
And it is with amino acids that modern combinatorial chemistry began. Mario Geysen, in the mid 1980s, began synthesizing peptides by the hundreds, first in parallel fashion and later as mixtures. The classic technique of solid phase synthesis, developed in the 1960s by R. Bruce Merrifield of Rockefeller University, quickly became the key to the production of entire proteins and enzymes during the past three decades. And it has also become the basis for the explosion of solid phase organic synthesis, whereby molecular diversity can be introduced by producing a nearly infinite variety of heterocycles, steroids, carbohydrates, and soon, organometallics, all while tethered by one reversible link to a suitable polymeric support. This dramatic detour from traditional methods of chemical research leads to all sorts of interesting questions. Will all possible compounds be prepared before today's graduate students complete their Ph.D.s? If Chemical Abstracts recorded only several million pure compounds in the past 50 years, but a lone undergraduate student can beat that total in a single afternoon of peptide synthesis, what will be left to make? And can there be any room for rationality in drug design in the future?
Copyright 2000 Arno F. Spatola |